STAT3 and familial pancreatic carcinoma: Using an HDAC3 inhibitor or knocking down HDAC3 weakens the binding of STAT3 to the PD-L1 promoter, thereby destroying the HDAC3/STAT3/PD-L1 signal transduction and improving the immunotherapy efficacy in pancreatic cancer [218].